Residency · Residency · Radiation Oncology
Radiation Dermatitis and Supportive Care During Treatment
Introduction
Radiation dermatitis is the most common acute side effect experienced by patients undergoing radiation therapy, affecting up to 95% of those receiving curative-intent treatment. The severity of radiation dermatitis can vary widely, ranging from mild erythema to severe moist desquamation and, in rare cases, ulceration. Effective prevention and management of radiation dermatitis are crucial to maintaining the quality of treatment, ensuring patient comfort, and promoting adherence to the prescribed treatment schedule. This lecture provides an overview of the pathophysiology, grading systems, prevention strategies, and evidence-based management approaches for radiation-induced skin reactions.
Pathophysiology
Acute Radiation Dermatitis
Radiation therapy damages the basal layer of the epidermis, which impairs the normal renewal process of skin cells. This damage triggers the release of inflammatory mediators such as interleukin-1 (IL-1), tumor necrosis factor-alpha (TNF-alpha), and prostaglandins from irradiated keratinocytes. These inflammatory signals cause vascular dilation and increased capillary permeability, leading to erythema and edema in the affected skin. At higher radiation doses, the basal layer can be completely lost, resulting in moist desquamation. Clinically, acute radiation dermatitis typically begins one to two weeks after starting treatment and reaches its peak near the end of treatment or within one to two weeks after completion.
Late Skin Changes
Months to years after radiation therapy, late skin changes may develop, including fibrosis of the dermis and subcutaneous tissue. Permanent vascular damage can cause telangiectasia, while pigmentation changes manifest as either hyperpigmentation or hypopigmentation. Additionally, chronic radiation effects can lead to skin atrophy and loss of adnexal structures such as hair follicles and sweat glands.
Grading Systems
CTCAE v5.0 Radiation Dermatitis Grading
The Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 classifies radiation dermatitis into five grades. Grade 1 involves faint erythema or dry desquamation. Grade 2 is characterized by moderate to brisk erythema, patchy moist desquamation primarily confined to skin folds, and moderate edema. Grade 3 includes moist desquamation occurring in areas other than skin folds and creases, along with bleeding induced by minor trauma or abrasion. Grade 4 represents life-threatening consequences such as skin necrosis or ulceration involving the full thickness of the dermis and spontaneous bleeding. Grade 5 corresponds to death related to radiation dermatitis.
RTOG Acute Skin Toxicity Scale
The Radiation Therapy Oncology Group (RTOG) acute skin toxicity scale uses a similar grading system from 0 to 4. Grade 2 is defined by tender or bright erythema, patchy moist desquamation, and moderate edema. Grade 3 involves confluent moist desquamation greater than 1.5 cm in diameter, occurring outside of skin folds, accompanied by pitting edema.
Risk Factors
Patient Factors
Several patient-related factors influence the risk of developing radiation dermatitis. Individuals with fair skin phototypes (Fitzpatrick I-II) are more susceptible to erythema, whereas those with darker skin tones are at higher risk for hyperpigmentation. Obesity contributes to increased risk due to skin folds creating a bolus effect and trapping moisture. Smoking impairs wound healing, increasing susceptibility to skin toxicity. Patients with connective tissue disorders such as lupus or scleroderma exhibit increased sensitivity to radiation. Diabetes also impairs healing capacity. Concurrent chemotherapy, especially with agents like taxanes, anthracyclines, and epidermal growth factor receptor (EGFR) inhibitors, further elevates the risk.
Treatment Factors
Treatment-related factors that increase the severity of radiation dermatitis include higher total radiation dose and dose per fraction, as well as larger treatment volumes. The use of bolus material increases skin dose and thus toxicity. Tangential beam arrangements, commonly used in breast radiation therapy, can contribute to skin reactions. Skin folds within the treatment field, such as the axilla, inframammary region, and inguinal area, are prone to moist desquamation. Concurrent administration of radiosensitizing agents also heightens the risk.
Anatomic Factors
Certain anatomical sites are more vulnerable due to thin skin or high friction. These include the axilla, groin, perineum, and neck folds. In breast radiation, the inframammary fold is the most common site for moist desquamation. In head and neck radiation, areas behind the ears and neck folds are frequently affected.
Prevention Strategies
Skin Care During Treatment
Gentle skin washing with mild soap and lukewarm water is recommended and is not harmful, dispelling the historical myth that washing should be avoided. Patients should avoid harsh detergents, fragrances, and alcohol-based products. After washing, the skin should be patted dry rather than rubbed. Wearing loose-fitting, soft clothing over the treatment area helps minimize irritation. Sun exposure should be avoided, and mineral-based sunscreens with SPF 30 or higher are advised for irradiated skin.
Prophylactic Topical Agents
Emollients and moisturizers such as aqueous cream, aloe vera, and calendula ointment are commonly used. Notably, calendula ointment has demonstrated superiority over trolamine in preventing grade 2 or higher dermatitis in randomized trials. These agents should be applied two to three times daily throughout the treatment course. Topical corticosteroids, particularly mometasone furoate 0.1% cream, have shown efficacy in reducing the incidence of grade 2 or higher dermatitis, as evidenced by the RTOG 1311 trial in breast cancer patients. Mometasone should be applied once daily to irradiated skin starting at the initiation of treatment. Silver sulfadiazine has some evidence supporting its use in preventing moist desquamation but is not routinely recommended prophylactically. Hyaluronic acid-based products are emerging as potential radioprotective agents, though further clinical trials are needed to confirm their efficacy.
IMRT and Advanced Techniques
Advanced radiation techniques such as intensity-modulated radiation therapy (IMRT) and volumetric modulated arc therapy (VMAT) can reduce hot spots in skin folds, thereby decreasing skin toxicity. Prone breast positioning is effective in reducing dose to the inframammary fold. The use of bolus should be avoided unless specifically required for target coverage to minimize skin dose.
Management of Acute Radiation Dermatitis
Grade 1 (Dry Desquamation)
For grade 1 dermatitis, continuing regular moisturizing is recommended. Hydrocortisone 1% cream can be used to alleviate pruritus. Patients should be monitored for any progression of skin changes.
Grade 2 (Moist Desquamation - Skin Folds)
Management of grade 2 dermatitis involves the use of absorbent non-adherent dressings such as Mepilex Lite or hydrogel sheets. Silver-containing dressings like Mepilex Ag provide antibacterial protection. Gentle wound care is essential, keeping the affected area clean and dry between dressing changes. Topical corticosteroids, such as mometasone 0.1%, may be applied to erythematous areas but should be avoided on open wounds. Pain management includes topical analgesics and systemic analgesics as needed.
Grade 3 (Confluent Moist Desquamation)
Grade 3 dermatitis requires adherence to moist wound healing principles using non-adherent, absorbent dressings. Antimicrobial coverage may be provided by silver sulfadiazine or medical-grade honey. It is important to assess for secondary infection, which may present with purulence, increased pain, expanding erythema, or fever. If infection is suspected, wound cultures should be obtained, and topical or systemic antibiotics initiated accordingly. Treatment breaks should be avoided if possible, and any necessary interruptions should be discussed with the radiation oncologist.
Grade 4 (Skin Necrosis/Ulceration)
Grade 4 dermatitis is rare and necessitates consultation with wound care specialists. Treatment interruption may be required. Surgical debridement is indicated if necrotic tissue is present. It is also important to rule out underlying tumor involvement or other etiologies contributing to skin necrosis.
Special Considerations
Breast Cancer Radiation
Moist desquamation of the inframammary fold occurs in 30-50% of patients receiving conventional fractionation for breast cancer. Hypofractionation, delivering 40-42.5 Gy in 15-16 fractions, has been shown to reduce overall skin toxicity compared to conventional fractionation. Prone positioning is beneficial for patients with large breasts. Prophylactic use of mometasone and barrier films can further mitigate skin reactions.
Head and Neck Radiation
Concurrent cisplatin chemotherapy increases the severity of radiation dermatitis in head and neck cancer patients. Moist desquamation commonly occurs in the posterior neck folds during radiation to this region. EGFR inhibitors such as cetuximab cause a papulopustular rash that is distinct from radiation dermatitis but may overlap clinically.
Perineal and Vulvar Radiation
Moist desquamation is nearly universal in patients receiving radiation to the perineal and vulvar areas. Supportive care includes sitz baths, barrier creams, and meticulous hygiene. Effective pain management is critical to ensure treatment adherence in this sensitive region.
Supportive Care Beyond Dermatitis
Fatigue Management
Fatigue is the most common systemic side effect of radiation therapy, affecting 70-80% of patients. Exercise programs have demonstrated benefits in reducing cancer-related fatigue. Counseling on adequate nutrition and sleep hygiene is also important.
Nutritional Support
Nutritional support is particularly vital for patients undergoing head and neck, esophageal, or abdominal radiation therapy. Prophylactic percutaneous endoscopic gastrostomy (PEG) tube placement may be indicated for head and neck chemoradiation patients. Weekly weight monitoring and involvement of a dietitian are recommended to optimize nutritional status.
Psychosocial Support
Screening for anxiety and distress should occur at the initial consultation and throughout treatment. Referral to social work services can address practical needs such as transportation and financial toxicity. Survivorship planning should begin during the treatment phase to facilitate long-term care.
Key Clinical Pearls
Radiation dermatitis affects up to 95% of patients undergoing radiation therapy. Prophylactic use of moisturizers and topical corticosteroids, particularly mometasone 0.1%, are supported by evidence as effective prevention strategies. The current standard for managing moist desquamation is moist wound healing using non-adherent dressings; the outdated practice of keeping wounds dry should be avoided. Treatment breaks due to skin toxicity should be minimized whenever possible, as interruptions can compromise tumor control. Hypofractionation in breast cancer reduces overall skin toxicity compared to conventional fractionation. It is essential to assess for secondary infection in patients with grade 2 to 3 dermatitis, and wound cultures should be obtained before initiating empiric antibiotics.
References
- Wong RK, Bensadoun RJ, Boers-Doets CB, et al. Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. Support Care Cancer. 2013;21(10):2933-2948.
- Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol. 2008;26(13):2085-2092.
- Hindley A, Zain Z, Wood L, et al. Mometasone furoate cream reduces acute radiation dermatitis in patients receiving breast radiation therapy: results of a randomized trial. Int J Radiat Oncol Biol Phys. 2014;90(4):748-755.
- Rosenthal A, Israilevich R, Moy R. Management of acute radiation dermatitis: a review of the literature and proposal for treatment algorithm. J Am Acad Dermatol. 2019;81(2):558-567.